melanoma - search results
If you're not happy with the results, please do another search
The DREAMseq trial appears to provide convincing data that treatment order—with immunotherapy first over targeted therapy—leads to survival benefits.
New research leveraging machine learning has identified novel predictive biomarkers of response to immune checkpoint inhibitor (ICI) therapy for melanoma.
A team from the Netherlands Cancer Institute in Amsterdam have shown for the first time in a randomized, controlled trial that cell therapy can delay disease progression in patients with advanced melanoma when compared with standard immunotherapy.
In a paper published in Nature Cell Biology, researchers at Sanford Burnham Prebys have shown for the first time that inhibiting a key metabolic enzyme selectively kills melanoma cells and stops tumor growth.
Using a preclinical model, researchers have described key features of a gene mutation responsible for 15% to 20% of all melanomas.
Metastases from primary cancer tumors may remain dormant in distant tissues for many years or decades before they re-emerge and grow new tumors.
Cancer has been considered a disease of the genome. Recent studies, however, have begun to show the importance of the tumor's local microenvironment that nurtures and sustains these cells.
Research from the University of Michigan shows that a microfluidic device can detect circulating melanoma cells in blood, which could be used to diagnose and monitor the treatment of melanoma patients following further validation.
Researchers have created spatial maps of melanoma that show how individual cells interact as the cancer progresses. The maps reveal details of how melanoma suppresses the immune system as it takes over.
The FDA has approved the use of the anti-lymphocyte-activation gene (LAG)-3 agent relatlimab in combination with the anti-programmed death (PD)-1 drug nivolumab for patients with treatment-naïve advanced melanoma.